Novo Nordisk A/S Says Blood Drugs Could Hold Blockbuster Potential

Two hemophilia drugs being developed by Danish drugmaker Novo Nordisk could hold blockbuster potential though sales of its only hemophilia drug on the market will be flat this year, its chief science officer said. Novo Nordisk aims for a hemophilia drug candidate, Vatreptacog, to replace at least part of the 8.3 billion crowns ($1.48 billion) in annual sales of its only hemophilia drug now in the market, NovoSeven, as sales of that drug decline. "Vatreptacog can hopefully take over the market which NovoSeven has today," Mads Krogsgaard Thomsen told Reuters in an interview on Tuesday.